GSK二季度核心业绩超预期并宣布加速研发计划，但全年EPS指引下调至区间低端且盘中已重定价

Nasdaq cuts most of its losses, Dow surges on extended oil slide, solid earnings
Introduction & Market Context
GSK (NYSE:GSK) presented its Q2 2026 results and "Accelerate Growth" strategy on July 28, 2026, revealing stronger-than-expected quarterly performance and an aggressive pipeline acceleration plan. The pharmaceutical giant reported sales of £8.4 billion, up 5% at constant exchange rates, with core operating profit rising 7% and core earnings per share climbing 9%. The company’s shares rose 3.35% to $53.78 in premarket trading following the presentation, reflecting investor confidence in the strategic transformation underway.
The presentation outlined a comprehensive strategy to accelerate late-stage R&D development, with management announcing more than 20 Phase 3 trial starts planned for 2026—double the original target. This pipeline expansion is being funded by a new "Accelerate Growth" program targeting £1.9 billion in annual cost savings by 2029, with the majority of those savings being reinvested into the company’s specialty medicines portfolio.
Quarterly Performance Highlights
GSK’s second quarter demonstrated the company’s ongoing transformation from a diversified pharmaceutical business to a specialty-focused biopharma. As illustrated in the following financial summary, the quarter showed strong momentum across key metrics:
The company’s specialty medicines business led growth with sales of £3.8 billion, up 14% year-over-year, while vaccines contributed £2.3 billion, an 8% increase. General medicines declined 9% to £2.3 billion, reflecting ongoing pricing pressure and patent expirations in mature markets. This performance pattern aligns with management’s strategic pivot toward higher-margin specialty franchises.
Product-level performance revealed broad-based strength across the specialty portfolio, as shown in the detailed sales driver analysis:
Key growth drivers included Arexvy, the respiratory syncytial virus vaccine, which more than doubled sales, and Nucala, the IL-5 inhibitor, which grew 23% driven by its COPD indication launch. The company’s long-acting injectable HIV franchise also showed exceptional momentum, with Cabenuva up 33% and Apretude up 39%. Emerging oncology assets Jemperli and Blenrep both posted strong growth of 27% and over 100%, respectively.
Detailed Financial Analysis
The quarter’s financial performance demonstrated significant operational leverage and margin expansion. As detailed in the comprehensive profit and loss breakdown:
Gross margin improved 250 basis points to 77.4% on a constant currency basis, benefiting from favorable product mix as higher-margin specialty medicines gained share. The company noted that last year’s comparator also contributed to the improvement. Selling, general and administrative expenses rose 5%, driven by the phasing of commercial investments, while research and development spending increased 13%, reflecting the accelerated pipeline investment strategy.
Core operating margin expanded 60 basis points to 33.3%, with management highlighting that the improvement came despite significantly increased R&D spending. Core earnings per share of 50.5 pence benefited from both operational improvements and a 1% boost from share buyback programs. Total results were impacted by a £1.9 billion impairment charge related to camlipixant, the P2X3 receptor antagonist for refractory chronic cough, which failed to meet endpoints in late-stage trials.
Cash generation remained robust, with £4.3 billion generated from operations in the first half of 2026, up from £3.7 billion in the prior year period. Free cash flow of £2.8 billion benefited from improved working capital management, a $400 million payment from the linerixibat out-license, and a $250 million special dividend from the ViiV Healthcare shareholding restructure. The company completed its acquisition of Nuvalent for a net cost of £7.1 billion on July 15, bringing precision oncology assets neladalkib and Jideytro into the portfolio.
Strategic Transformation: Accelerate Growth Program
Management unveiled a comprehensive restructuring program designed to reallocate resources toward late-stage pipeline development. The "Accelerate Growth" initiative targets £1.9 billion in annual cost savings by 2029, with approximately 90% of benefits expected by 2028. The program will cost £2.4 billion to implement, with £2.1 billion in cash costs spread across 2026-2029.
As illustrated in the revenue composition evolution, GSK is executing a fundamental business transformation:
The company’s revenue mix has shifted dramatically since 2016, with specialty medicines and vaccines growing from a minority of sales to an increasingly dominant position. Management projects that specialty medicines will exceed 50% of total sales by 2031, up from approximately 45% in 2026. This transformation is supported by a compound annual growth rate of approximately 8% from 2021-2026, accelerating from 4% in the 2016-2021 period.
The cost savings program breaks down into three main categories: approximately 45% from streamlining support services and enhanced procurement, 40% from reallocating resources away from mature general medicines toward specialty products, and 15% from supply chain simplification. Management emphasized that the majority of savings would be reinvested into the late-stage pipeline rather than flowing entirely to the bottom line, though some margin benefit is expected.
Pipeline Acceleration and R&D Strategy
The centerpiece of GSK’s presentation was a dramatic acceleration in late-stage clinical development. The company announced plans to initiate more than 20 Phase 3 studies in 2026, a significant increase from the 10 starts disclosed at the Q1 update and more than double the seven starts in 2024. This acceleration is illustrated in the Phase 3 momentum data:
The acceleration encompasses seven key assets across 18 indications and 25 Phase 3 studies, spanning oncology (11 studies), respiratory (9 studies), hepatology (4 studies), and vaccines (1 study). Management attributed this rapid expansion to improved R&D productivity, with full clinical development cycle times improving by more than 25% compared to 2016-2020 averages.
The comprehensive pipeline roadmap shows the timing and breadth of upcoming regulatory milestones:
Near-term regulatory submissions in 2026 include multiple oncology assets: dostarlimab for rectal cancer, Jideytro and neladalkib for non-small cell lung cancer, velzatinib for gastrointestinal stromal tumors, and several antibody-drug conjugates including mocertatug rezetecan and risvutatug rezetecan across multiple gynecologic and solid tumor indications. The respiratory portfolio includes depemokimab (Exdensur) for COPD and EGPA, while the HIV franchise advances three-times-yearly dosing regimens for both treatment and prevention.
Management detailed specific acceleration decisions across the portfolio:
The company implemented a new portfolio review process involving senior leadership and cross-functional teams to identify opportunities for accelerated development. This resulted in expedited timelines for multiple assets, with several programs advancing from Phase 1b to Phase 3 in as little as 15 months. The review process focuses on validated targets with clear efficacy or tolerability advantages over existing standards of care.
Oncology: Building a Competitive Pipeline
GSK outlined its oncology strategy, emphasizing precision medicine and antibody-drug conjugates across high-value tumor types. The market opportunity analysis reveals significant potential:
The company is targeting cancers with substantial unmet need, including lung cancer ($72 billion market by 2031), prostate cancer ($30 billion), and multiple hematologic and gynecologic malignancies. Management emphasized that many of these indications have poor five-year survival rates and limited treatment options, creating opportunities for differentiated therapies.
The oncology pipeline centers on three main platforms: precision kinase inhibitors for lung cancer (neladalkib and Jideytro for ALK+ and ROS1+ NSCLC, velzatinib for GIST), antibody-drug conjugates targeting B7-H4 and B7-H3 (mocertatug rezetecan and risvutatug rezetecan), and immune checkpoint inhibitors (dostarlimab, Jemperli). The company also continues to advance Blenrep, its BCMA-directed ADC for multiple myeloma, into earlier treatment lines.
Clinical data presented for the ADC programs showed compelling efficacy signals. Mocertatug rezetecan demonstrated a 62% confirmed objective response rate in platinum-resistant ovarian cancer and 67% in second-line endometrial cancer, comparing favorably to other ADCs in development. Risvutatug rezetecan showed broad activity across multiple solid tumors, with particularly strong data in small cell lung cancer (60% ORR) and prostate cancer (37% ORR in the total mCRPC population).
Management announced that risvutatug rezetecan achieved the first positive Phase 3 overall survival data for any B7-H3 targeting ADC in second-line small cell lung cancer (ARTEMIS-008 study), with detailed results to be presented in H2 2026. The company plans to initiate multiple additional Phase 3 studies across lung, prostate, pancreatic, gastric, bladder, and gynecologic cancers.
Respiratory, Hepatology & Vaccines: Expanding Beyond T2 Inflammation
GSK’s respiratory and hepatology strategy focuses on addressing diseases driven by inflammation and fibrosis, extending beyond traditional Type 2 inflammation targets. The portfolio addresses interconnected disease biology:
The company highlighted COPD as a major opportunity, noting it is the third leading cause of death globally with approximately 400 million patients worldwide, yet only two classes of biologics are currently available. GSK is developing a differentiated portfolio with four distinct mechanisms: Nucala (IL-5, approved), depemokimab/Exdensur (ultra long-acting IL-5, Phase 3), ULA TSLP/GSK’283 (six-monthly dosing, Phase 3 starts H2 2026), and LA IL33/GSK’995 (quarterly dosing, Phase 3 start H1 2027).
Management emphasized that COPD is not primarily a Type 2 inflammatory disease for most patients, making IL33 inhibition particularly attractive as it represents the first true T2-agnostic mechanism of action. The company is designing studies with COPD-specific cardiopulmonary composite endpoints to capture the full benefit of IL33 inhibition.
In hepatology, GSK is advancing two major programs. Bepirovirsen, an antisense oligonucleotide for chronic hepatitis B, demonstrated functional cure rates of 49% in patients with baseline HBsAg ≤3,000 IU/ml and 62% in those with ≤1,000 IU/ml in the B-Well 1 and 2 studies. The company filed for regulatory approval with a PDUFA date of October 26, 2026. Efimosfermin, an FGF21 analog for MASH, showed 24 percentage points of fibrosis improvement in F2/F3 patients, competitive with or superior to other agents in development, with the added benefit of monthly rather than weekly dosing.
The vaccines business is exploring broader protective benefits beyond infectious disease prevention. Real-world evidence studies suggest Shingrix may be associated with reduced dementia risk (ranging from 17-51% risk reduction across multiple studies) and cardiovascular events (16-43% reduction). The company initiated a Phase 3 study to evaluate Shingrix for MACE prevention, starting in H2 2026, and is conducting two large pragmatic randomized controlled trials in Denmark (162,000 patients) and Finland (34,000 patients) to assess dementia and cardiovascular outcomes.
HIV: Long-Acting Injectables Reshape Market Dynamics
The HIV market is undergoing a fundamental shift from daily oral therapies to long-acting injectables, creating significant growth opportunities for GSK’s ViiV Healthcare joint venture. Market projections show this transformation:
The global HIV treatment market is projected to grow from approximately £22 billion in 2025 to £25 billion by 2035, with long-acting injectables capturing an increasingly large share. In the US prevention market, the shift is even more dramatic, with the market expected to double from £3 billion to £6 billion, driven primarily by LAI adoption.
GSK’s current LAI franchise—Cabenuva (monthly treatment) and Apretude (every-two-months prevention)—is performing strongly, with 80% of HIV growth driven by the LAI portfolio. The company reported that LAIs now represent 35% of total US HIV sales, with 77% of Cabenuva product switches coming from competitors.
The pipeline includes three major near-term growth drivers: three-times-yearly cabotegravir plus rilpivirine for treatment (Phase 3 started June 2026), three-times-yearly cabotegravir for prevention (pivotal data H2 2026, approval expected 2027), and twice-yearly VH184 plus VH499 for treatment (Phase 2b ongoing, Phase 3 start 2028). Management emphasized that the three-times-yearly regimen would reduce patient treatment days from 365 to just 3 annually while doubling clinic LAI capacity.
The company presented data showing VH184, a third-generation integrase inhibitor, demonstrates superior in vitro potency against second-generation INSTI resistance mutations compared to bictegravir, while VH499, a capsid inhibitor, shows no CYP3A-mediated drug-drug interactions. This profile is designed to maximize the eligible patient population for the twice-yearly regimen.
Financial Outlook and Long-Term Targets
GSK updated its 2026 financial guidance, moving sales and core operating profit expectations to the upper half of the previously announced 3-5% and 7-9% growth ranges, respectively. Core EPS guidance shifted to the lower half of the 7-9% range, primarily reflecting approximately £160 million of incremental interest expense from the Nuvalent acquisition. The company maintained its 70 pence dividend guidance and expects to generate approximately £10 billion in cash from operations.
The detailed modeling considerations and long-term outlook were presented as follows:
Management reiterated its ambition to exceed £40 billion in sales by 2031, with specialty medicines representing more than 50% of the total. The company now expects stable to improving operating margins through the dolutegravir loss of exclusivity period (2028-2030), a meaningful upgrade from previous guidance that had suggested margin pressure during this period. The improvement reflects confidence in the Accelerate Growth program’s ability to offset the impact of generic competition for GSK’s HIV franchise.
Beyond 2031, management projects accelerating growth driven by the expanded late-stage pipeline. The company’s track record of consistent execution was highlighted:
From 2021 through 2026, GSK has delivered compound annual growth rates of at least 8% for sales, at least 9% for R&D investment, at least 13% for core operating profit, and more than 540 basis points of operating margin expansion. Management emphasized that this performance demonstrates the company’s ability to simultaneously invest in growth while expanding profitability.
The company expects core operating profit and core EPS growth to be significantly weighted toward the fourth quarter of 2026, reflecting the timing of productivity charges taken in late 2025, Nuvalent consolidation costs in Q3 2026, and the phasing of commercial investments. For modeling purposes, management provided detailed assumptions including gross margin benefits from product mix and efficiencies, broadly stable SG&A as a percentage of sales, R&D growing significantly ahead of sales, royalty income of £850-900 million, and a core tax rate of approximately 17.5%.
Investment Considerations
GSK’s Q2 2026 presentation outlined a company in the midst of significant strategic transformation, with strong near-term execution supporting an ambitious long-term vision. The quarter’s financial beat—with revenue of $11.15 billion versus $8.25 billion expected and EPS of $0.68 versus $0.47 expected—demonstrates operational momentum across the specialty medicines and vaccines portfolios.
The dramatic acceleration of the late-stage pipeline, with more than 20 Phase 3 starts in 2026 compared to seven in 2024, represents a fundamental shift in R&D productivity and strategic focus. Management’s decision to reallocate £1.9 billion in annual cost savings primarily toward pipeline investment rather than near-term margin expansion signals confidence in the growth potential of assets like mocertatug rezetecan, risvutatug rezetecan, depemokimab, bepirovirsen, and the long-acting HIV franchise.
Key risks include execution challenges in delivering the complex Accelerate Growth restructuring program, clinical and regulatory uncertainties inherent in the expanded pipeline, integration risks from the Nuvalent acquisition, and the impact of dolutegravir’s loss of exclusivity on HIV franchise profitability. The company’s increased net debt of £15.1 billion following the Nuvalent acquisition also reduces financial flexibility, though strong cash generation of £4.3 billion in the first half provides some cushion.
According to InvestingPro analysis, GSK shares appear significantly undervalued at current levels, trading at a P/E ratio of 14.43 and a PEG ratio of just 0.15, suggesting the market may not be fully pricing in the company’s near-term earnings growth potential. With shares at $53.78, up 3.35% following the presentation, the stock remains well below its 52-week high of $61.70, potentially offering an attractive entry point for investors confident in management’s ability to execute its transformation strategy.
The presentation makes clear that GSK is moving decisively to reshape itself into a specialty-focused biopharma with industry-leading positions in oncology, respiratory, HIV, and vaccines. Whether this transformation generates sufficient returns to justify the significant R&D investment and restructuring costs will depend on clinical trial outcomes, regulatory approvals, and commercial execution over the next several years. The company’s upgraded 2026 guidance and improved long-term margin outlook suggest management has increasing confidence in this strategy’s viability.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.